Olymviq 4mg FlexTouch is used for:

• Chronic weight management: It may be used along with a reduced-calorie diet and increased physical activity in appropriate adults with obesity or overweight and a weight-related health condition.

• Cardiovascular risk reduction: Semaglutide may reduce the risk of major cardiovascular events in certain adults with obesity or overweight and established cardiovascular disease.

Olymviq contains Semaglutide, which activates GLP-1 receptors involved in appetite and blood sugar regulation.

It slows stomach emptying, increases feelings of fullness and reduces hunger and food intake. Semaglutide also supports blood sugar regulation by increasing insulin release when blood sugar levels are high and reducing glucagon release.

Tell your doctor about all medicines, supplements and herbal products you take.

• Insulin or sulfonylureas: These may increase the risk of low blood sugar when used with Semaglutide.

• Oral medicines: Delayed stomach emptying may affect the absorption of some medicines taken by mouth.

• Other GLP-1 receptor agonists: Do not use Olymviq with another Semaglutide-containing medicine or GLP-1 receptor agonist unless prescribed.

• Medicines requiring monitoring: Tell your doctor if you use medicines that require regular monitoring.

• Store Olymviq 4mg FlexTouch in a refrigerator at 2°C to 8°C.

• Do not freeze.

• Do not use the pen if it has been frozen.

• Protect the pen from light.

• Keep it out of reach of children.

• Follow the product packaging for instructions after first use.

Use Olymviq 4mg FlexTouch exactly as prescribed.

The 4mg/3mL pen is designed to deliver 1mg doses. It is injected under the skin once weekly into the abdomen, thigh or upper arm.

The dose may be increased gradually depending on the treatment plan. Do not assume that the 4mg stated on the pen is the amount to inject at one time.

Do not inject into a vein or muscle. Use a new needle for each injection and do not share the pen.

Common side effects include 

• Nausea 

• vomiting 

• diarrhoea 

• constipation

• abdominal pain 

• decreased appetite 

• headache 

• dizziness.

Serious side effects:

• Severe or persistent abdominal pain

• Severe allergic reactions

• Persistent vomiting or diarrhoea with dehydration

• Gallstones or gallbladder inflammation

• Sudden or worsening changes in vision

• Low blood sugar when used with insulin or sulfonylureas

Seek medical attention if severe or persistent symptoms occur.

• Remember that the 4mg on the pen is the total Semaglutide content, not the weekly dose.

• Use Olymviq on the same day each week.

• Rotate injection sites.

• Follow your recommended diet and physical activity plan.

• Drink enough fluids if gastrointestinal side effects occur.

• Tell your doctor before surgery or deep sedation.

• Do not combine Olymviq with another GLP-1 receptor agonist unless prescribed.